"目录号: HY-15284A
Prasugrel盐酸盐是血小板抑制剂，IC50为1.8 μM。
相关产品
Suramin sodium salt-Clopidogrel hydrogen sulfate-Ticagrelor-MRS 2578-Prasugrel-AZD1283-N6-(4-Hydroxybenzyl)adenosine-Diquafosol tetrasodium-Denufosol tetrasodium-
生物活性
Description
Prasugrel hydrochloride is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel hydrochloride is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel hydrochloride reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel hydrochloride AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia; Nausea; Epistaxis
Clinical Trial
University of Florida
Coronary Artery Disease
October 2014
Phase 4
University of Pecs
Acute Coronary Syndrome
September 2011
Phase 4
Daiichi Sankyo Inc.
Coronary Artery Disease
November 2010
Phase 4
Eli Lilly and Company-Daiichi Sankyo Inc.
Sickle Cell Disease
November 2011
Phase 2
VA Office of Research and Development
Coronary Artery Bypass
February 1, 2013
Phase 3
Eli Lilly and Company
Acute Coronary Syndrome
May 2010
Phase 2
Daiichi Sankyo Inc.
Coronary Artery Disease
February 2010
Phase 4
University of Florida
Coronary Artery Disease
August 2010
Phase 4
University of Patras
Platelet Reactivity
June 2012
Phase 3
Eli Lilly and Company-Daiichi Sankyo Co., Ltd.
Anemia, Sickle Cell
July 2010
Phase 1
University of Florida
Coronary Artery Disease
January 2012
University of Florida
Diabetes Mellitus-Coronary Artery Disease
February 2013
Medstar Health Research Institute
Acute Coronary Syndrome
December 2010
Phase 4
Gennaro Sardella-University of Roma La Sapienza
ST-Elevation Myocardial Infarction
May 2013
Phase 3
Dong-A University
Acute Coronary Syndromes
October 2013
Phase 3
Eli Lilly and Company
Healthy Volunteers
March 2009
Phase 1
Dong-A University
Coronary Artery Disease
December 2011
Phase 3
Gennaro Sardella-University of Roma La Sapienza
Acute Coronary Syndrome
October 2011
Phase 3
Dong-A University
ST-Segment Elevation Myocardial Infarction
January 2014
Phase 3
Gennaro Sardella-University of Roma La Sapienza
Coronary Artery Disease
March 2013
Phase 3
Asan Medical Center
Healthy
July 2013
Phase 1
The Medicines Company
Coronary Artery Disease
June 2013
Phase 2
Eli Lilly and Company
Sickle Cell Disease
September 2011
Phase 1
Gyeongsang National University Hospital
Acute Coronary Syndrome-Platelet Thrombus-Bleeding
July 2013
Phase 4
University of Florida
Coronary Artery Disease
March 2014
Phase 4
Faculty Hospital Kralovske Vinohrady
Myocardial Infarction-Angioplasty, Balloon, Coronary-Platelet Aggregation Inhibitors
January 2013
Phase 4
Eli Lilly and Company-Daiichi Sankyo Inc.
Acute Coronary Syndrome
March 2007
Phase 2
University of Patras
Coronary Artery Disease (CAD)
February 2011
Phase 3
David Antoniucci-A.R. CARD Onlus Foundation-Careggi Hospital
Adverse Reaction to Antiplatelet Agent-Acute Coronary Syndrome
November 2012
Phase 4
Dong-A University
Acute Coronary Syndrome
September 2012
Phase 3
Tufts Medical Center
Coronary Artery Disease
July 2013
Phase 4
Daiichi Sankyo Inc.-Eli Lilly and Company
Coronary Artery Disease
March 2012
Phase 4
University of Florida
Coronary Artery Disease-Acute Coronary Syndrome
March 2014
University of Patras
Hemodialysis-Chronic Renal Failure
May 2010
Phase 3
Eli Lilly and Company-Daiichi Sankyo Inc.
Healthy Volunteers
July 2012
Phase 1
University of Patras
Coronary Artery Disease (CAD)-Acute Coronary Syndrome (ACS)
April 2010
Phase 3
Yochai Birnbaum-AstraZeneca-Baylor College of Medicine
Cardiovascular Disease
February 2016
Phase 2
University of Patras
Platelet Reactivity
October 2011
Phase 4
Deutsches Herzzentrum Muenchen
Coronary Heart Disease
September 2011
Phase 4
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-Andaluz Health Service
Diabetes Mellitus Type II-Acute Coronary Syndrome
October 2012
Phase 4
Eli Lilly and Company-Daiichi Sankyo Inc.
Sickle Cell Anemia
July 2010
Phase 2
University of Patras
Platelet Reactivity
October 2011
Phase 4
Eli Lilly and Company-Daiichi Sankyo Inc.
Sickle Cell Disease
April 2013
Phase 3
Asan Medical Center
Healthy
January 2014
Phase 1
Federal University of São Paulo
Acute Coronary Syndrome-Platelet Function
July 2013
Phase 4
University of Roma La Sapienza
Coronary Artery Disease
July 2012
Phase 3
Seoul National University Hospital-Boston Scientific Korea Co. Ltd-Dio-Terumo Corporation
Acute Coronary Syndrome
July 2014
Phase 4
University of Patras
Myocardial Infarction
April 2011
Phase 3
LifeBridge Health-AstraZeneca
Coronary Artery Disease
January 2014
Phase 4
University of Cologne
Acute Coronary Syndrome-Unstable Angina
October 2014
Phase 3
Deutsches Herzzentrum Muenchen-Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Acute Coronary Syndrome (ACS)
September 2013
